Squarepoint
SLDB icon

Squarepoint’s Solid Biosciences SLDB Stock Holding History

Squarepoint’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Sell
44,769
-5,285
-11% -$34K ﹤0.01% 3651
2025
Q4 		$282K Buy
+50,054
New +$271K ﹤0.01% 3644
2025
Q2 		– Sell
-105,682
Closed -$391K – 5002
2025
Q1 		$391K Buy
+105,682
New +$452K ﹤0.01% 3517
2024
Q4 		– Sell
-12,463
Closed -$86.9K – 5458
2024
Q3 		$86.9K Sell
12,463
-4,926
-28% -$40K ﹤0.01% 3902
2024
Q2 		$98.6K Buy
+17,389
New +$156K ﹤0.01% 3802
2021
Q3 		– Sell
-888
Closed -$49K – 3381
2021
Q2 		$49K Sell
888
-4,725
-84% -$312K ﹤0.01% 3108
2021
Q1 		$466K Buy
+5,613
New +$621K ﹤0.01% 2077
2020
Q4 		– Sell
-807
Closed -$25K – 3229
2020
Q3 		$25K Buy
+807
New +$30.9K ﹤0.01% 2410
2020
Q1 		– Sell
-4,947
Closed -$330K – 2447
2019
Q4 		$330K Buy
+4,947
New +$546K ﹤0.01% 1992
2019
Q3 		– Sell
-873
Closed -$75K – 2646
2019
Q2 		$75K Buy
+873
New +$95.2K ﹤0.01% 2257
2019
Q1 		– Sell
-1,631
Closed -$656K – 2411
2018
Q4 		$656K Buy
1,631
+286
+21% +$134K 0.01% 1107
2018
Q3 		$952K Buy
+1,345
New +$845K 0.01% 1018

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Squarepoint's SLDB Position: Q1 2026 in Review

Squarepoint reduced its Solid Biosciences (SLDB) stake by 11% in Q1 2026, selling an estimated $34K and leaving 44,769 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #3651.

Squarepoint first reported a position in SLDB in Q3 2018 and has held it in 12 quarters since. The position peaked at $952K in Q3 2018. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Squarepoint held 44,769 shares of Solid Biosciences worth $322K as of Q1 2026.
  • Squarepoint sold 5,285 Solid Biosciences shares in Q1 2026, an estimated $34K.
  • Solid Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3651 holding.
  • Squarepoint first reported a position in Solid Biosciences in Q3 2018 and has held it in 12 quarters since.
  • Squarepoint's Solid Biosciences position peaked at $952K in Q3 2018.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.